Products
Loncastuximab Biosimilar Antibody-Drug Conjugate (CD19) for Research
Pre-Made Loncastuximab biosimilar, Whole mAb ADC, Anti-CD19 Antibody: Anti-B4/CVID3 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Loncastuximab tesirine is an antibody-drug conjugate designed to target human CD19. It is a humanized monoclonal antibody and conjugated to SG3199, a pyrrolobenzodiazepine (PBD) dimer cytotoxin by a protease enzyme cleavable valine-alanine linker.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-ab-320-1mg | 1mg | |
| GMP-Bios-ab-320-10mg | 10mg | |
| GMP-Bios-ab-320-100mg | 100mg | |
| GMP-Bios-ab-320-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Loncastuximab biosimilar, Whole mAb ADC, Anti-CD19 Antibody: Anti-B4/CVID3 therapeutic antibody |
| INN Name | Loncastuximab |
| Target | CD19 |
| Format | Whole mAb ADC |
| Derivation | Chimeric (Mouse/Human) |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | 6ani:HL:IM |
| 95-98% SI Structure | None |
| Year Proposed | 2017 |
| Year Recommended | 2018 |
| Companies | ADC Therapeutics |
| Conditions Approved | Diffuse large B cell lymphoma |
| Conditions Active | Follicular lymphoma;Mantle-cell lymphoma;Non-Hodgkin's lymphoma |
| Conditions Discontinued | Precursor B-cell lymphoblastic leukaemia-lymphoma |
| Development Tech | na |
About target - CD19
1. Protein B-lymphocyte antigen CD19
2. Gene CD19
3. Organism Homo sapiens (Human)
Function
Functions as coreceptor for the B-cell antigen receptor complex (BCR) on B-lymphocytes. Decreases the threshold for activation of downstream signaling pathways and for triggering B-cell responses to antigens (PubMed:2463100, PubMed:1373518, PubMed:16672701).
Activates signaling pathways that lead to the activation of phosphatidylinositol 3-kinase and the mobilization of intracellular Ca2+ stores (PubMed:9382888, PubMed:9317126, PubMed:12387743, PubMed:16672701).
Is not required for early steps during B cell differentiation in the blood marrow (PubMed:9317126).
Required for normal differentiation of B-1 cells (By similarity).
Required for normal B cell differentiation and proliferation in response to antigen challenges (PubMed:2463100, PubMed:1373518).
Required for normal levels of serum immunoglobulins, and for production of high-affinity antibodies in response to antigen challenge (PubMed:9317126, PubMed:12387743, PubMed:16672701).
